OncoMatch/Clinical Trials/NCT06626230
Safety of Anal Curcumin
Is NCT06626230 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Curcuminoid Capsules for anal high grade squamous intraepithelial lesion.
Treatment: Curcuminoid Capsules — The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Prior therapy
Lab requirements
Blood counts
no grade 2 or higher hematology abnormality
Kidney function
no grade 2 or higher renal abnormality
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Grady Memorial Hospital · Atlanta, Georgia
- Grady Hospital - Ponce De Leon Clinic · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06626230 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify